Analysis of Fascin-1 in Relation to Gleason Risk Classification and Nuclear ETS-Related Gene Status of Human Prostate Carcinomas: An Immunohistochemical Study of Clinically Annotated Tumours From the Wales Cancer Bank
Although prostate-specific antigen (PSA) testing can identify early-stage prostate cancers, additional biomarkers are needed for risk stratification. In one study, high levels of the actin-bundling protein, fascin-1, were correlated with lethal-phase, hormone-refractory prostate cancer. Analyses of...
Gespeichert in:
| Veröffentlicht in: | Biomarkers in cancer 2017, Vol.2017 (9), p.1179299X17710944-1179299X17710944 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1179299X17710944 |
|---|---|
| container_issue | 9 |
| container_start_page | 1179299X17710944 |
| container_title | Biomarkers in cancer |
| container_volume | 2017 |
| creator | Jefferies, Matthew T Pope, Christopher S Kynaston, Howard G Clarke, Alan R Martin, Richard M Adams, Josephine C |
| description | Although prostate-specific antigen (PSA) testing can identify early-stage prostate cancers, additional biomarkers are needed for risk stratification. In one study, high levels of the actin-bundling protein, fascin-1, were correlated with lethal-phase, hormone-refractory prostate cancer. Analyses of independent samples are needed to establish the value of fascin-1 as a possible biomarker. We examined fascin-1 by immunohistochemistry in tumour specimens from the Wales Cancer Bank in comparison with nuclear-located ETS-related gene (ERG), an emerging marker for aggressive prostate cancer. Fascin-1 was elevated in focal areas of a minority of tumours, yet fascin-1-positivity did not differentiate tumours of low-, intermediate-, or high-risk Gleason scores and did not correlate with PSA status or biochemical relapse after surgery. Stromal fascin-1 correlated with high Gleason score. Nuclear ERG was upregulated in tumours but not in stroma. The complexities of fascin-1 status indicate that fascin-1 is unlikely to provide a suitable biomarker for prediction of aggressive prostate cancers. |
| doi_str_mv | 10.1177/1179299X17710944 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5457026</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_1179299X17710944</sage_id><sourcerecordid>1909233120</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3624-3cdf781df73393ae27191d71fcc8cafcf9ac88513aa497e8917786ef7bf388eb3</originalsourceid><addsrcrecordid>eNp9Uk1v1DAQjRCIVqV3TsgSFy6hdpxsYg5I21V3W6kC1C6CmzXrTLpu_VHsBGl_Kv-m3g9Kuwd8sEcz772xnyfL3jL6kbG6PkmbKIT4mWJGRVm-yA7XqXyde_kkPsiOY7ylaZWUiap6nR0UzYjWVVkeZn_GDswq6kh8R6YQlXY5I9qRKzTQa-9I78nMIMQUXul4RyYGYtSdVtsyuJZ8GVRCBHI2v843PGzJDB2S6x76YSN9Plhw5FvwMaWQTCCkTt5C_ETGjlxYOzi_1LH3aok2aZvEHdrVmjox2q0zZpWgzvcb-flg_RAimQZvSb9E8gMMxqTrFAZyCu7uTfaqAxPxeHceZd-nZ_PJeX75dXYxGV_mio-KMueq7eqGpY1zwQGLmgnW1qxTqlHQqU6AapqKcYBS1NiIZHczwq5edLxpcMGPss9b3fthYbFV6PoARt4HbSGspActn1ecXsob_1tWZVXTYpQEPuwEgv81YOyl1VGhMeDQD1EyQUXBOStogr7fg94mF9IPRlnQhlUVFaJOKLpFqWR3DNg9XoZRuR4duT86ifLu6SMeCX8HJQHyLSDCDf7r-h_BnStGLzD0EEFBm34WnhmzV1QglbdyxKuCPwAv3udl</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2081550997</pqid></control><display><type>article</type><title>Analysis of Fascin-1 in Relation to Gleason Risk Classification and Nuclear ETS-Related Gene Status of Human Prostate Carcinomas: An Immunohistochemical Study of Clinically Annotated Tumours From the Wales Cancer Bank</title><source>PubMed Central Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Jefferies, Matthew T ; Pope, Christopher S ; Kynaston, Howard G ; Clarke, Alan R ; Martin, Richard M ; Adams, Josephine C</creator><creatorcontrib>Jefferies, Matthew T ; Pope, Christopher S ; Kynaston, Howard G ; Clarke, Alan R ; Martin, Richard M ; Adams, Josephine C</creatorcontrib><description>Although prostate-specific antigen (PSA) testing can identify early-stage prostate cancers, additional biomarkers are needed for risk stratification. In one study, high levels of the actin-bundling protein, fascin-1, were correlated with lethal-phase, hormone-refractory prostate cancer. Analyses of independent samples are needed to establish the value of fascin-1 as a possible biomarker. We examined fascin-1 by immunohistochemistry in tumour specimens from the Wales Cancer Bank in comparison with nuclear-located ETS-related gene (ERG), an emerging marker for aggressive prostate cancer. Fascin-1 was elevated in focal areas of a minority of tumours, yet fascin-1-positivity did not differentiate tumours of low-, intermediate-, or high-risk Gleason scores and did not correlate with PSA status or biochemical relapse after surgery. Stromal fascin-1 correlated with high Gleason score. Nuclear ERG was upregulated in tumours but not in stroma. The complexities of fascin-1 status indicate that fascin-1 is unlikely to provide a suitable biomarker for prediction of aggressive prostate cancers.</description><identifier>ISSN: 1179-299X</identifier><identifier>EISSN: 1179-299X</identifier><identifier>DOI: 10.1177/1179299X17710944</identifier><identifier>PMID: 28607544</identifier><language>eng</language><publisher>London, England: SAGE Publishing</publisher><subject>Actin ; Authorship ; Biomarkers ; Biopsy ; Colon ; Immunohistochemistry ; Medical research ; Metastasis ; Mortality ; Original Research ; Pancreatic cancer ; Patients ; Peer review ; Prostate cancer ; Prostate carcinoma ; Prostate-specific antigen ; Proteins ; Stroma ; Studies ; Surgery ; Systematic review ; Tumors</subject><ispartof>Biomarkers in cancer, 2017, Vol.2017 (9), p.1179299X17710944-1179299X17710944</ispartof><rights>The Author(s) 2017</rights><rights>2017. This work is published under http://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s) 2017 2017 SAGE Publications Ltd unless otherwise noted. Manuscript content on this site is licensed under Creative Commons Licenses</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3624-3cdf781df73393ae27191d71fcc8cafcf9ac88513aa497e8917786ef7bf388eb3</citedby><cites>FETCH-LOGICAL-c3624-3cdf781df73393ae27191d71fcc8cafcf9ac88513aa497e8917786ef7bf388eb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5457026/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5457026/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,4024,27923,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28607544$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jefferies, Matthew T</creatorcontrib><creatorcontrib>Pope, Christopher S</creatorcontrib><creatorcontrib>Kynaston, Howard G</creatorcontrib><creatorcontrib>Clarke, Alan R</creatorcontrib><creatorcontrib>Martin, Richard M</creatorcontrib><creatorcontrib>Adams, Josephine C</creatorcontrib><title>Analysis of Fascin-1 in Relation to Gleason Risk Classification and Nuclear ETS-Related Gene Status of Human Prostate Carcinomas: An Immunohistochemical Study of Clinically Annotated Tumours From the Wales Cancer Bank</title><title>Biomarkers in cancer</title><addtitle>Biomark Cancer</addtitle><description>Although prostate-specific antigen (PSA) testing can identify early-stage prostate cancers, additional biomarkers are needed for risk stratification. In one study, high levels of the actin-bundling protein, fascin-1, were correlated with lethal-phase, hormone-refractory prostate cancer. Analyses of independent samples are needed to establish the value of fascin-1 as a possible biomarker. We examined fascin-1 by immunohistochemistry in tumour specimens from the Wales Cancer Bank in comparison with nuclear-located ETS-related gene (ERG), an emerging marker for aggressive prostate cancer. Fascin-1 was elevated in focal areas of a minority of tumours, yet fascin-1-positivity did not differentiate tumours of low-, intermediate-, or high-risk Gleason scores and did not correlate with PSA status or biochemical relapse after surgery. Stromal fascin-1 correlated with high Gleason score. Nuclear ERG was upregulated in tumours but not in stroma. The complexities of fascin-1 status indicate that fascin-1 is unlikely to provide a suitable biomarker for prediction of aggressive prostate cancers.</description><subject>Actin</subject><subject>Authorship</subject><subject>Biomarkers</subject><subject>Biopsy</subject><subject>Colon</subject><subject>Immunohistochemistry</subject><subject>Medical research</subject><subject>Metastasis</subject><subject>Mortality</subject><subject>Original Research</subject><subject>Pancreatic cancer</subject><subject>Patients</subject><subject>Peer review</subject><subject>Prostate cancer</subject><subject>Prostate carcinoma</subject><subject>Prostate-specific antigen</subject><subject>Proteins</subject><subject>Stroma</subject><subject>Studies</subject><subject>Surgery</subject><subject>Systematic review</subject><subject>Tumors</subject><issn>1179-299X</issn><issn>1179-299X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>AFRWT</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9Uk1v1DAQjRCIVqV3TsgSFy6hdpxsYg5I21V3W6kC1C6CmzXrTLpu_VHsBGl_Kv-m3g9Kuwd8sEcz772xnyfL3jL6kbG6PkmbKIT4mWJGRVm-yA7XqXyde_kkPsiOY7ylaZWUiap6nR0UzYjWVVkeZn_GDswq6kh8R6YQlXY5I9qRKzTQa-9I78nMIMQUXul4RyYGYtSdVtsyuJZ8GVRCBHI2v843PGzJDB2S6x76YSN9Plhw5FvwMaWQTCCkTt5C_ETGjlxYOzi_1LH3aok2aZvEHdrVmjox2q0zZpWgzvcb-flg_RAimQZvSb9E8gMMxqTrFAZyCu7uTfaqAxPxeHceZd-nZ_PJeX75dXYxGV_mio-KMueq7eqGpY1zwQGLmgnW1qxTqlHQqU6AapqKcYBS1NiIZHczwq5edLxpcMGPss9b3fthYbFV6PoARt4HbSGspActn1ecXsob_1tWZVXTYpQEPuwEgv81YOyl1VGhMeDQD1EyQUXBOStogr7fg94mF9IPRlnQhlUVFaJOKLpFqWR3DNg9XoZRuR4duT86ifLu6SMeCX8HJQHyLSDCDf7r-h_BnStGLzD0EEFBm34WnhmzV1QglbdyxKuCPwAv3udl</recordid><startdate>2017</startdate><enddate>2017</enddate><creator>Jefferies, Matthew T</creator><creator>Pope, Christopher S</creator><creator>Kynaston, Howard G</creator><creator>Clarke, Alan R</creator><creator>Martin, Richard M</creator><creator>Adams, Josephine C</creator><general>SAGE Publishing</general><general>SAGE Publications</general><general>Sage Publications Ltd</general><scope>AFRWT</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TO</scope><scope>8FE</scope><scope>8FH</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AYAGU</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>2017</creationdate><title>Analysis of Fascin-1 in Relation to Gleason Risk Classification and Nuclear ETS-Related Gene Status of Human Prostate Carcinomas: An Immunohistochemical Study of Clinically Annotated Tumours From the Wales Cancer Bank</title><author>Jefferies, Matthew T ; Pope, Christopher S ; Kynaston, Howard G ; Clarke, Alan R ; Martin, Richard M ; Adams, Josephine C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3624-3cdf781df73393ae27191d71fcc8cafcf9ac88513aa497e8917786ef7bf388eb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Actin</topic><topic>Authorship</topic><topic>Biomarkers</topic><topic>Biopsy</topic><topic>Colon</topic><topic>Immunohistochemistry</topic><topic>Medical research</topic><topic>Metastasis</topic><topic>Mortality</topic><topic>Original Research</topic><topic>Pancreatic cancer</topic><topic>Patients</topic><topic>Peer review</topic><topic>Prostate cancer</topic><topic>Prostate carcinoma</topic><topic>Prostate-specific antigen</topic><topic>Proteins</topic><topic>Stroma</topic><topic>Studies</topic><topic>Surgery</topic><topic>Systematic review</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jefferies, Matthew T</creatorcontrib><creatorcontrib>Pope, Christopher S</creatorcontrib><creatorcontrib>Kynaston, Howard G</creatorcontrib><creatorcontrib>Clarke, Alan R</creatorcontrib><creatorcontrib>Martin, Richard M</creatorcontrib><creatorcontrib>Adams, Josephine C</creatorcontrib><collection>SAGE Journals</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Australia & New Zealand Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Biological Science Database</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Biomarkers in cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jefferies, Matthew T</au><au>Pope, Christopher S</au><au>Kynaston, Howard G</au><au>Clarke, Alan R</au><au>Martin, Richard M</au><au>Adams, Josephine C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Analysis of Fascin-1 in Relation to Gleason Risk Classification and Nuclear ETS-Related Gene Status of Human Prostate Carcinomas: An Immunohistochemical Study of Clinically Annotated Tumours From the Wales Cancer Bank</atitle><jtitle>Biomarkers in cancer</jtitle><addtitle>Biomark Cancer</addtitle><date>2017</date><risdate>2017</risdate><volume>2017</volume><issue>9</issue><spage>1179299X17710944</spage><epage>1179299X17710944</epage><pages>1179299X17710944-1179299X17710944</pages><issn>1179-299X</issn><eissn>1179-299X</eissn><abstract>Although prostate-specific antigen (PSA) testing can identify early-stage prostate cancers, additional biomarkers are needed for risk stratification. In one study, high levels of the actin-bundling protein, fascin-1, were correlated with lethal-phase, hormone-refractory prostate cancer. Analyses of independent samples are needed to establish the value of fascin-1 as a possible biomarker. We examined fascin-1 by immunohistochemistry in tumour specimens from the Wales Cancer Bank in comparison with nuclear-located ETS-related gene (ERG), an emerging marker for aggressive prostate cancer. Fascin-1 was elevated in focal areas of a minority of tumours, yet fascin-1-positivity did not differentiate tumours of low-, intermediate-, or high-risk Gleason scores and did not correlate with PSA status or biochemical relapse after surgery. Stromal fascin-1 correlated with high Gleason score. Nuclear ERG was upregulated in tumours but not in stroma. The complexities of fascin-1 status indicate that fascin-1 is unlikely to provide a suitable biomarker for prediction of aggressive prostate cancers.</abstract><cop>London, England</cop><pub>SAGE Publishing</pub><pmid>28607544</pmid><doi>10.1177/1179299X17710944</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1179-299X |
| ispartof | Biomarkers in cancer, 2017, Vol.2017 (9), p.1179299X17710944-1179299X17710944 |
| issn | 1179-299X 1179-299X |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5457026 |
| source | PubMed Central Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Actin Authorship Biomarkers Biopsy Colon Immunohistochemistry Medical research Metastasis Mortality Original Research Pancreatic cancer Patients Peer review Prostate cancer Prostate carcinoma Prostate-specific antigen Proteins Stroma Studies Surgery Systematic review Tumors |
| title | Analysis of Fascin-1 in Relation to Gleason Risk Classification and Nuclear ETS-Related Gene Status of Human Prostate Carcinomas: An Immunohistochemical Study of Clinically Annotated Tumours From the Wales Cancer Bank |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T08%3A12%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Analysis%20of%20Fascin-1%20in%20Relation%20to%20Gleason%20Risk%20Classification%20and%20Nuclear%20ETS-Related%20Gene%20Status%20of%20Human%20Prostate%20Carcinomas:%20An%20Immunohistochemical%20Study%20of%20Clinically%20Annotated%20Tumours%20From%20the%20Wales%20Cancer%20Bank&rft.jtitle=Biomarkers%20in%20cancer&rft.au=Jefferies,%20Matthew%20T&rft.date=2017&rft.volume=2017&rft.issue=9&rft.spage=1179299X17710944&rft.epage=1179299X17710944&rft.pages=1179299X17710944-1179299X17710944&rft.issn=1179-299X&rft.eissn=1179-299X&rft_id=info:doi/10.1177/1179299X17710944&rft_dat=%3Cproquest_pubme%3E1909233120%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2081550997&rft_id=info:pmid/28607544&rft_sage_id=10.1177_1179299X17710944&rfr_iscdi=true |